Swedish MPA approves an additional injection of Diamyd® in ongoing clinical pilot trial

The Swedish MPA has approved an extension of DIAGNODE-1, an open label clinical pilot trial where the diabetes vaccine Diamyd® is administered directly into the lymph node. The extension refers to three adult patients included in the trial who now will be offered a fourth injection of Diamyd®.“The approval gives us the opportunity to evaluate the safety and immune response of a fourth so called booster injection, and whether we can further extend the effect of intralymphatic Diamyd® treatment on preserving the endogenous insulin production”, says Johnny Ludvigsson, Professor at Linköping